Abstract
Diabetes mellitus is a major risk factor for the development of cardiovascular disease due to increased vascular inflammatory and oxidative stress favouring atherogenesis. Endothelial dysfunction has received increasing attention as a potential contributor to the pathogenesis of vascular disease in diabetes mellitus. Although the underlying cause of endothelial dysfunction is multifactorial, a key factor is impairment of the bioavailability of nitric oxide (NO). Emerging evidence suggest that upregulation of arginase is of central importance for reduced NO bioavailability due to competition for the substrate L-arginine between arginase and the endothelial form of NO synthase. Arginase is also associated with increased oxidative stress, further impairing NO bioavailability. Upregulation of arginase has been suggested to be a key factor driving endothelial dysfunction in diabetes. The present review describes the regulation of arginase in relation to diabetes and arginase as a potential therapeutic target to improve endothelial function in experimental models and the clinical setting of diabetes mellitus.
Keywords: Arginase, nitric oxide, oxidative stress, endothelium, diabetes.
Graphical Abstract
Current Vascular Pharmacology
Title:The Emerging Role of Arginase in Endothelial Dysfunction in Diabetes
Volume: 14 Issue: 2
Author(s): John Pernow and Christian Jung
Affiliation:
Keywords: Arginase, nitric oxide, oxidative stress, endothelium, diabetes.
Abstract: Diabetes mellitus is a major risk factor for the development of cardiovascular disease due to increased vascular inflammatory and oxidative stress favouring atherogenesis. Endothelial dysfunction has received increasing attention as a potential contributor to the pathogenesis of vascular disease in diabetes mellitus. Although the underlying cause of endothelial dysfunction is multifactorial, a key factor is impairment of the bioavailability of nitric oxide (NO). Emerging evidence suggest that upregulation of arginase is of central importance for reduced NO bioavailability due to competition for the substrate L-arginine between arginase and the endothelial form of NO synthase. Arginase is also associated with increased oxidative stress, further impairing NO bioavailability. Upregulation of arginase has been suggested to be a key factor driving endothelial dysfunction in diabetes. The present review describes the regulation of arginase in relation to diabetes and arginase as a potential therapeutic target to improve endothelial function in experimental models and the clinical setting of diabetes mellitus.
Export Options
About this article
Cite this article as:
Pernow John and Jung Christian, The Emerging Role of Arginase in Endothelial Dysfunction in Diabetes, Current Vascular Pharmacology 2016; 14 (2) . https://dx.doi.org/10.2174/1570161114666151202205617
DOI https://dx.doi.org/10.2174/1570161114666151202205617 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Climate Changes and Human Health: A Review of the Effect of Environmental Stressors on Cardiovascular Diseases Across Epidemiology and Biological Mechanisms
Current Pharmaceutical Design Role of α- and β-adrenergic Mechanisms in the Pathogenesis of Pulmonary Injuries Characterized by Edema, Inflammation and Fibrosis
Cardiovascular & Hematological Disorders-Drug Targets Meet Our Editorial Board Member
Mini-Reviews in Organic Chemistry The Influence of Erythropoietin and Proinflammatory Cytokines in the Development of Cerebral Palsy
Vascular Disease Prevention (Discontinued) The Physiological/Pathophysiological Significance of Vitamin D in Cancer, Cardiovascular Disorders and Beyond
Current Drug Metabolism Neuroinflammation in Alzheimer’s Disease: Microglia, Molecular Participants and Therapeutic Choices
Current Alzheimer Research Efficacy of Enzyme Replacement Therapy in Fabry Disease
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Cardiovascular Changes in Menopause
Current Cardiology Reviews Determination of Homocysteine in Human Saliva by Liquid Chromatography and Electrospray Ionization Quadrupole Time-of-flight Mass Spectrometry: Profiles in Healthy Adults
Protein & Peptide Letters HDL - Cholesterol: The New Target for Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Topiramate: Its Pharmacological Properties and Therapeutic Efficacy in Epilepsy
Mini-Reviews in Medicinal Chemistry Matrix Metalloproteinases and Vulnerable Atheromatous Plaque
Current Topics in Medicinal Chemistry Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Should We be Concerned About the Inflammatory Response to Endovascular Procedures?
Current Vascular Pharmacology Preventing Vascular Graft Failure: Endothelial Cell Seeding and Tissue Engineering
Vascular Disease Prevention (Discontinued) Stroke in Women
Recent Patents on Cardiovascular Drug Discovery High Altitude Hypoxia
Current Proteomics New Approaches in the Treatment of Overactive Bladder: Targeting Adrenergic Receptors and Neurokinin Receptors
Current Medicinal Chemistry - Central Nervous System Agents Uric Acid and Diabetes: Is there a Link?
Current Pharmaceutical Design Multiple Drug Targets in the Management of Type 2 Diabetes
Current Drug Targets